Ⅲ期非小细胞肺癌放化疗后度伐利尤单抗治疗的真实世界多中心研究
该多中心回顾性分析比较147例Ⅲ期非小细胞肺癌放化疗后接受度伐利尤单抗治疗的患者与121例仅接受放化疗的历史队列。度伐利尤单抗组中位总生存未达到,历史组为26.9个月(HR 0.56,95%CI 0.37-0.85,p=0.001)。PD-L1≥50%者12个月OS似有改善,发生肺炎为负性预后因素。
要点
- 放化疗后度伐利尤单抗较单纯放化疗改善总生存(HR 0.56)。
- PD-L1≥50%者12个月OS似更优(100% vs 86%)。
- 发生任何级别肺炎者12个月OS更低(85% vs 95%)。
核心结论
- 真实世界多中心分析提示,Ⅲ期NSCLC放化疗后度伐利尤单抗治疗与历史队列相比总生存改善。
- PD-L1表达≥50%与度伐利尤单抗治疗后有利OS相关,而发生肺炎为负性预后因素。
研究设计与样本
- 多中心回顾性分析,度伐利尤单抗组147例Ⅲ期NSCLC患者,历史对照队列121例仅接受放化疗患者。
- 采用Kaplan-Meier法估计生存曲线,单因素分析用log-rank检验,多因素分析评估标准预后因素对度伐利尤单抗使用的影响。
主要发现
- 度伐利尤单抗组中位OS未达到,历史组为26.9个月(HR 0.56,95%CI 0.37-0.85,p=0.001)。
- 度伐利尤单抗组PD-L1≥50%者12个月OS为100% vs 86%(HR 0.25,95%CI 0.11-0.58,p=0.007)。
- PD-L1 1-49%与PD-L1<1%患者之间OS无差异。
- 度伐利尤单抗启动延迟超过42天未影响OS。
- 度伐利尤单抗组与历史组肺炎发生率相似;度伐利尤单抗组发生任何级别肺炎者12个月OS低于无肺炎者(85% vs 95%,HR 3.3,95%CI 1.2-9.0,p=0.006)。
关键数值与推荐
- PD-L1≥50%者12个月OS 100% vs 86%(HR 0.25,95%CI 0.11-0.58,p=0.007)。
- 启动延迟超过42天未影响OS。
- 发生任何级别肺炎者12个月OS 85% vs 95%(HR 3.3,95%CI 1.2-9.0,p=0.006)。
临床怎么用
- 支持Ⅲ期NSCLC放化疗后使用度伐利尤单抗,PD-L1≥50%者可能获益更明显。
- 度伐利尤单抗启动延迟超过42天似不影响OS,可结合临床情况安排。
- 需关注肺炎发生,发生肺炎者预后较差。
局限性
- 为回顾性多中心分析,与历史队列比较可能存在混杂偏倚。
- PD-L1亚组与肺炎预后分析基于度伐利尤单抗组内数据,样本量有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The PACIFIC trial demonstrated that durvalumab therapy following chemoradiation (CRT) was associated with improved overall survival (OS) in patients with stage III non-small cell lung cancer (NSCLC). It is unclear whether the results obtained as part of randomised controlled trials are a reflection of real-world (RW) data. Several questions remain unanswered with regard to RW durvalumab use, such as optimal time to durvalumab initiation, incidence of pneumonitis and response in PD-L1 subgroups. METHODS: In this multicentre retrospective analysis, 147 patients with stage III NSCLC treated with CRT followed by durvalumab were compared with a historical cohort of 121 patients treated with CRT alone. Survival curves were estimated using the Kaplan-Meier method and compared with the log-rank test in univariate analysis. Multivariate analysis was performed to evaluate the effect of standard prognostic factors for durvalumab use. RESULTS: Median OS was not reached in the durvalumab group, compared with 26.9 months in the historical group (hazard ratio [HR]: 0.56, 95% confidence interval [CI]: 0.37-0.85, p = 0.001). In the durvalumab group, our data suggest improved 12-month OS in patients with PD-L1 expression ≥50% (100% vs 86%, HR: 0.25, 95% CI: 0.11-0.58, p = 0.007). There was no difference in OS between patients with a PD-L1 expression of 1-49% and patients with PD-L1 expression <1%. Delay in durvalumab initiation beyond 42 days did not impact OS. Incidence of pneumonitis was similar in the durvalumab and historical groups. In the durvalumab group, patients who experienced any-grade pneumonitis had a lower 12-month OS than patients without pneumonitis (85% vs 95%, respectively; HR: 3.3, 95% CI: 1.2-9.0, p = 0.006). CONCLUSIONS: This multicentre analysis suggests that PD-L1 expression ≥50% was associated with favourable OS in patients with stage III NSCLC treated with durvalumab after CRT, whereas the presence of pneumonitis represented a negative prognostic factor.
引用
- Desilets A, Blanc-Durand F, Lau S, et al. Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre study. Eur J Cancer. 2020. PMID: 33242835. doi:10.1016/j.ejca.2020.10.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。